


PHARMACEUTICAL 2022

Metacrine Inc. Rank 392 of 475





PHARMACEUTICAL 2022

Metacrine Inc. Rank 392 of 475

The relative strengths and weaknesses of Metacrine Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Metacrine Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Metacrine Inc. is the variable Net Income, reducing the Economic Capital Ratio by 270% points.

The company's Economic Capital Ratio, given in the ranking table, is -395%, being 118% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	78,740
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,760
Liabilities, Non-Current	0
Other Assets	902
Other Compr. Net Income	-6.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,128
Property and Equipment	347
Research and Development	45,474
Revenues	0
Selling, General and Administrative Expense	15,605

Output Variable	Value in 1000 USD
Assets	79,989
Liabilities	7,760
Expenses	61,079
Stockholders Equity	72,229
Net Income	-62,207
Comprehensive Net Income	-62,210
Economic Capital Ratio	-395%